| scholarly article | Q13442814 |
| P2093 | author name string | Hyun-Joo Lee | |
| Myung-Shin Jeon | |||
| Si-Na Kim | |||
| Sun U Song | |||
| TacGhee Yi | |||
| P2860 | cites work | Expression of galectin-3 modulates T-cell growth and apoptosis | Q24309392 |
| Dysregulated T cell expression of TIM3 in multiple sclerosis | Q24676780 | ||
| Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells | Q24681395 | ||
| Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications | Q27004008 | ||
| Multilineage potential of adult human mesenchymal stem cells | Q27860737 | ||
| Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway | Q28184967 | ||
| Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance | Q28214490 | ||
| Biological activities of ecalectin: a novel eosinophil-activating factor | Q28217186 | ||
| Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer | Q28245761 | ||
| The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity | Q28281686 | ||
| Galectins: structure, function and therapeutic potential | Q28283659 | ||
| Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance | Q28511160 | ||
| Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells | Q28572966 | ||
| Mesenchymal stem cells in health and disease | Q29614296 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Human adipose tissue is a source of multipotent stem cells | Q29617385 | ||
| Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats | Q82730941 | ||
| Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis | Q83014784 | ||
| Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells | Q84579882 | ||
| Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation | Q84875272 | ||
| Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice | Q84918699 | ||
| Mesenchymal stem cells reside in virtually all post-natal organs and tissues | Q29617740 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction | Q30847683 | ||
| Mesenchymal stem cell therapy: Two steps forward, one step back | Q33898653 | ||
| Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease | Q34112417 | ||
| Mesenchymal stromal cells: current understanding and clinical status | Q34234464 | ||
| Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines | Q34292905 | ||
| TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines | Q34997144 | ||
| Galectins as inflammatory mediators | Q35646669 | ||
| Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9 | Q35876978 | ||
| Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion | Q36381148 | ||
| Galectin-1: a small protein with major functions | Q36535706 | ||
| Mesenchymal stromal cells | Q36629367 | ||
| Protein-glycan interactions in the control of innate and adaptive immune responses | Q37168156 | ||
| The immunological potential of galectin-1 and -3. | Q37343666 | ||
| Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation | Q37443866 | ||
| Mesenchymal Stem Cells: Mechanisms of Inflammation | Q37809081 | ||
| New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins | Q37825539 | ||
| Mesenchymal stromal cell 'licensing': a multistep process | Q37880625 | ||
| Therapeutic potential of Galectin-9 in human disease | Q37906466 | ||
| Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications | Q37988754 | ||
| Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders | Q38035446 | ||
| Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation | Q38103925 | ||
| Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells | Q38360800 | ||
| Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion | Q38500880 | ||
| Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death | Q40333858 | ||
| Presentation of Galectin-1 by Extracellular Matrix Triggers T Cell Death | Q40616445 | ||
| Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression | Q42502186 | ||
| Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes | Q42622277 | ||
| Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. | Q42922142 | ||
| Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice | Q43407813 | ||
| Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation | Q44317237 | ||
| Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response | Q45147481 | ||
| Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. | Q45834735 | ||
| Mesenchymal stem cells induce apoptosis of activated T cells | Q46622786 | ||
| Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. | Q54333062 | ||
| Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. | Q54396842 | ||
| Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17 | Q62735747 | ||
| Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms | Q74183464 | ||
| Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1 | Q78127337 | ||
| Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis | Q80726697 | ||
| P433 | issue | 5 | |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 241-251 | |
| P577 | publication date | 2015-10-26 | |
| P1433 | published in | Immune Network | Q26841916 |
| P1476 | title | Galectin-9 is Involved in Immunosuppression Mediated by Human Bone Marrow-derived Clonal Mesenchymal Stem Cells | |
| P478 | volume | 15 |
| Q33850012 | Comparison of anticancer activities of Korean Red Ginseng-derived fractions |
| Q50115221 | EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis |
| Q58803547 | Extracellular galectins as controllers of cytokines in hematological cancer |
| Q64230450 | Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling |
| Q98735426 | Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors |
| Q39430866 | Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance. |
| Q99419092 | Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas lpr mice |
| Q90282382 | Syngeneic Mesenchymal Stem Cells Reduce Immune Rejection After Induced Pluripotent Stem Cell-Derived Allogeneic Cardiomyocyte Transplantation |
| Q47987935 | Transplantation of human bone marrow-derived clonal mesenchymal stem cells reduces fibrotic scar formation in a rat spinal cord injury model |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.